The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression
Open accessAbstract
Tumor progression relies on the ability of cancer cells to effectively invade surrounding tissues and propagate. Among the many mechanisms that contribute to tumor progression is the epithelial-to-mesenchymal transition (EMT), a phenotypic plasticity phenomenon that increases the cancer cells’ motility and invasiveness and influences their surrounding microenvironment by promoting the secretion of a variety of soluble factors. One such factor is IL-8, a chemokine with multiple pro-tumorigenic roles within the tumor microenvironment (TME), including stimulating proliferation or transformation of tumor cells into a migratory or mesenchymal phenotype. Further, IL-8 can increase tumor angiogenesis or recruit larger numbers of immunosuppressive cells to the tumor. Prognostically, observations in many tumor types show that patients with higher levels of IL-8 at baseline experience worse clinical outcomes. Additionally, studies have shown that the chemokine directly contributes to the development of resistance to both chemotherapy and molecularly targeted agents. More recently, clinical studies evaluating levels of IL-8 in patients receiving immune checkpoint inhibition (ICI) therapy deduced that myeloid tumor infiltration driven by IL-8 contributes to resistance to ICI agents and that peripheral IL-8 can predict outcomes to ICI therapy. Further, pre-clinical data demonstrate that targeting IL-8 or its receptors enables improved tumor killing by immune cells, and treatment strategies combining blockade of the IL-8/IL-8R axis with ICI ultimately improve anti-tumor efficacy. Based on these results and the prognostic capacity of IL-8, there are a number of ongoing clinical trials evaluating the addition of IL-8 targeting strategies to immune-based therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
The Interleukin-8 Pathway in Cancer
Waugh, D. J. J., & Wilson, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4843 · Cited by 2,103
Brabletz, T., Kalluri, R., Nieto, M. A., & Weinberg, R. A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.118 · Cited by 1,961
Neutrophil Extracellular Traps: Double-Edged Swords of Innate Immunity
Kaplan, M. J., & Radic, M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201719 · Cited by 1,171
Roussos, E. T., Condeelis, J. S., & Patsialou, A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3078 · Cited by 896
The CXCL8-CXCR1/2 pathways in cancer
Liu, Q., Li, A., Tian, Y., Wu, J. D., Liu, Y., Li, T., Chen, Y., Han, X., & Wu, K. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.08.002 · Cited by 662
Schalper, K. A., Carleton, M., Zhou, M., Chen, T., Feng, Y., Huang, S.-P., Walsh, A. M., Baxi, V., Pandya, D., Baradet, T., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0856-x · Cited by 548
Ostrand-Rosenberg, S., & Fenselau, C. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701019 · Cited by 509
Sanmamed, M. F., Perez-Gracia, J. L., Schalper, K. A., Fusco, J. P., Gonzalez, A., Rodriguez-Ruiz, M. E., Oñate, C., Perez, G., Alfaro, C., Martín-Algarra, S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx190 · Cited by 458
Yuan, S., Norgard, R. J., & Stanger, B. Z. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0015 · Cited by 455
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
Yuen, K. C., Liu, L.-F., Gupta, V., Madireddi, S., Keerthivasan, S., Li, C., Rishipathak, D., Williams, P., Kadel, E. E., Koeppen, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0860-1 · Cited by 429
Alfaro, C., Teijeira, A., Oñate, C., Pérez, G., Sanmamed, M. F., Andueza, M. P., Alignani, D., Labiano, S., Azpilikueta, A., Rodriguez-Paulete, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2463 · Cited by 417
Fernando, R. I., Castillo, M. D., Litzinger, M., Hamilton, D. H., & Palena, C. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0156 · Cited by 400
Self-citationThe IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance
David, J., Dominguez, C., Hamilton, D., & Palena, C. (2016) · Vaccines · doi:10.3390/vaccines4030022 · Cited by 395
Self-citationPotential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases
Cheng, Y., Ma, X.-L., Wei, Y.-Q., & Wei, X.-W. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.01.005 · Cited by 344
EMT and Cancer: More Than Meets the Eye
Derynck, R., & Weinberg, R. A. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.04.026 · Cited by 313
Lee, Y. S., Choi, I., Ning, Y., Kim, N. Y., Khatchadourian, V, Yang, D., Chung, H. K., Choi, D., LaBonte, M. J., Ladner, R. D., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.177 · Cited by 292
Greene, S., Robbins, Y., Mydlarz, W. K., Huynh, A. P., Schmitt, N. C., Friedman, J., Horn, L. A., Palena, C., Schlom, J., Maeda, D. Y., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2625 · Cited by 280
Self-citationBilusic, M., Heery, C. R., Collins, J. M., Donahue, R. N., Palena, C., Madan, R. A., Karzai, F., Marté, J. L., Strauss, J., Gatti-Mays, M. E., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0706-x · Cited by 274
Self-citationCancer-associated fibroblasts-derived IL-8 mediates resistance to cisplatin in human gastric cancer
Zhai, J., Shen, J., Xie, G., Wu, J., He, M., Gao, L., Zhang, Y., Yao, X., & Shen, L. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.002 · Cited by 272
Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy
Sun, L., Clavijo, P. E., Robbins, Y., Patel, P., Friedman, J., Greene, S., Das, R., Silvin, C., Van Waes, C., Horn, L. A., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126853 · Cited by 237
Self-citationUnderstanding the Multifaceted Role of Neutrophils in Cancer and Autoimmune Diseases
Wang, X., Qiu, L., Li, Z., Wang, X.-Y., & Yi, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02456 · Cited by 226
Wu, J., Gao, F.-X., Wang, C., Qin, M., Han, F., Xu, T., Hu, Z., Long, Y., He, X.-M., Deng, X., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1310-0 · Cited by 187
Zhang, M., Huang, L., Ding, G., Huang, H., Cao, G., Sun, X., Lou, N., Wei, Q., Shen, T., Xu, X., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000308 · Cited by 172
Dominguez, C., McCampbell, K. K., David, J. M., & Palena, C. (2017) · JCI Insight · doi:10.1172/jci.insight.94296 · Cited by 170
Self-citationGermann, M., Zangger, N., Sauvain, M., Sempoux, C., Bowler, A. D., Wirapati, P., Kandalaft, L. E., Delorenzi, M., Tejpar, S., Coukos, G., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910681 · Cited by 164
Epithelial-mesenchymal transition and inflammation at the site of the primary tumor
Dominguez, C., David, J. M., & Palena, C. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.002 · Cited by 162
Self-citationXiao, P. G., Long, X., Zhang, L., Ye, Y., Guo, J., Liu, P., Zhang, R., Ning, J., Yu, W., Wei, F., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1440166 · Cited by 162
Tumor Plasticity and Resistance to Immunotherapy
Horn, L. A., Fousek, K., & Palena, C. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.02.001 · Cited by 156
Self-citationSerum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer
Feng, L., Qi, Q., Wang, P., Chen, H., Chen, Z., Meng, Z., & Liu, L. (2018) · Journal of International Medical Research · doi:10.1177/0300060518800588 · Cited by 125
Kahraman, D., Kahraman, T., & Çetin-Atalay, R. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0004 · Cited by 118
Glioblastoma Cell-Secreted Interleukin-8 Induces Brain Endothelial Cell Permeability via CXCR2
Dwyer, J., Hebda, J. K., Guelte, A. L., Galán‐Moya, E. M., Smith, S. S., Azzi, S., Bidère, N., & Gavard, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045562 · Cited by 113
Serum IL-6 and IL-8 Correlate with Prognostic Factors in Ovarian Cancer
Sanguinete, M. M. M., Oliveira, P. H. D., Martins-Filho, A., Micheli, D. C., Tavares‐Murta, B. M., Murta, E. F. C., & Nomelini, R. S. (2017) · Immunological Investigations · doi:10.1080/08820139.2017.1360342 · Cited by 110
Horn, L. A., Riskin, J., Hempel, H., Fousek, K., Lind, H., Hamilton, D. H., McCampbell, K. K., Maeda, D. Y., Zebala, J. A., Su, Z., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000326 · Cited by 97
Self-citationMechanisms and Αpplications of Ιnterleukins in Cancer Immunotherapy
Anestakis, D., Petanidis, S., Kalyvas, S., Nday, C. M., Tsave, O., Kioseoglou, E., & Salifoglou, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16011691 · Cited by 90
Hamilton, D. H., Huang, B., Fernando, R. I., Tsang, K.-Y., & Palena, C. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1894 · Cited by 84
Self-citationGeng, R., Tan, X., Wu, J., Pan, Z., Yi, M., Shi, W., Liu, R., Yao, C., Wang, G., Lin, J., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.400 · Cited by 79
Ning, Y., Cui, Y., Li, X., Cao, X., Chen, A., Xu, C., Cao, J., & Luo, X. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.022 · Cited by 75
Oyanagi, J., Koh, Y., Sato, K., Mori, K. P., Teraoka, S., Akamatsu, H., Kanai, K., Hayata, A., Tokudome, N., Akamatsu, K., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.03.020 · Cited by 73
Mao, F.-Y., Zhao, Y., Lv, Y.-P., Teng, Y., Kong, H., Liu, Y., Wu, X., Hao, C.-J., Chen, W., Duan, M., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0803-7 · Cited by 71
Zhang, B., Shi, L., Lu, S., Sun, X., Liu, Y., Li, H., Wang, X., Zhao, C., Zhang, H., & Wang, Y. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1028702 · Cited by 70
Dabkevičienė, D., Jonušienė, V., Žitkutė, V., Žalytė, E., Grigaitis, P., Kirvelienė, V., & Sasnauskienė, A. (2015) · Medical Oncology · doi:10.1007/s12032-015-0703-y · Cited by 68
IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib
Fernando, R. I., Hamilton, D. H., Dominguez, C. L., David, J. M., McCampbell, K. K., & Palena, C. (2016) · Oncotarget · doi:10.18632/oncotarget.9662 · Cited by 64
Self-citationYu, J., Ren, X., Chen, Y., Liu, P., Wei, X., Li, H., Ying, G., Chen, K., Winkler, H., & Hao, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056069 · Cited by 58
Devapatla, B. K., Sharma, A., & Woo, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139237 · Cited by 58
Chen, S., Lian, G., Li, J., Zhang, Q., Zeng, L., Yang, K., Huang, C., Li, Y., Chen, Y., & Huang, K. (2018) · Cancer Medicine · doi:10.1002/cam4.1824 · Cited by 55
Du, J., He, Y., Li, P., Wu, W., Chen, Y., & Ruan, H. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3584-x · Cited by 52
Dominguez, C. L., Tsang, K.-Y., & Palena, C. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.297 · Cited by 49
Self-citationTiainen, L., Hämäläinen, M., Luukkaala, T. H., Tanner, M., Lahdenperä, O., Vihinen, P., Jukkola‐Vuorinen, A., Karihtala, P., Moilanen, E., & Kellokumpu‐Lehtinen, P. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.03.006 · Cited by 49
Milošević, V., Kopecka, J., Salaroglio, I. C., Libener, R., Napoli, F., Izzo, S., Orecchia, S., Ananthanarayanan, P., Bironzo, P., Grosso, F., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32419 · Cited by 48
The Emerging Use of Immune Checkpoint Blockade in the Adjuvant Setting for Solid Tumors: A Review
Moujaess, E., Haddad, F., Eid, R., & Kourié, H. R. (2019) · Immunotherapy · doi:10.2217/imt-2019-0087 · Cited by 41
Zhang, T., Liu, L., Wei, L., Zeng, Y., Xu, H., Lan, Q., Su, P., & Chu, Z. (2019) · Oncology Reports · doi:10.3892/or.2019.7049 · Cited by 40
Cheng, M., Cai, W., Huang, W., Chen, Y. X., Wu, Z., Luo, P., & Yan, W. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.09.032 · Cited by 25
Pharmacological and immunological targeting of tumor mesenchymalization
David, J. M., Dominguez, C. L., & Palena, C. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.11.011 · Cited by 15
Self-citation
Cited by
Harnessing cytokines and chemokines for cancer therapy
Propper, D. J., & Balkwill, F. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00588-9 · Cited by 989
Interleukins in cancer: from biology to therapy
Briukhovetska, D., Dörr, J., Endres, S., Libby, P., Dinarello, C. A., & Kobold, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00363-z · Cited by 781
Cambier, S., Gouwy, M., & Proost, P. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-00974-6 · Cited by 591
The role of CXCL family members in different diseases
Zhou, C., Gao, Y., Ding, P., Wu, T., & Ji, G. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01524-9 · Cited by 286
Crosstalk of Inflammatory Cytokines within the Breast Tumor Microenvironment
Habanjar, O., Bingula, R., Decombat, C., Diab-Assaf, M., Caldefie-Chezet, F., & Delort, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044002 · Cited by 263
Metadata
- Authors
- Fousek, K., Horn, L. A., & Palena, C.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 219
- Pages
- 107692
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W3089199226
- Cited by
- 359
- References
- 55
- FWCI
- 9.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.